Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Liabilities and Shareholders Equity (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Liabilities and Shareholders Equity for 10 consecutive years, with $376.6 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 70.65% to $376.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, up 59.88% year-over-year, with the annual reading at $376.6 million for FY2025, 70.65% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $376.6 million at Akebia Therapeutics, up from $364.2 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $628.7 million in Q1 2021, with the low at $207.1 million in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $376.3 million, with a median of $350.8 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity plummeted 52.12% in 2023, then skyrocketed 75.8% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $529.3 million in 2021, then crashed by 32.74% to $356.1 million in 2022, then crashed by 32.12% to $241.7 million in 2023, then decreased by 8.7% to $220.7 million in 2024, then skyrocketed by 70.65% to $376.6 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $376.6 million, $364.2 million, and $345.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.